Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera

Yfat Yahalom-Ronen; Noam Erez; Morly Fisher; Hadas Tamir; Boaz Politi; Hagit Achdout; Sharon Melamed; Itai Glinert; Shay Weiss; Inbar Cohen-Gihon; Ofir Israeli; Marina Izak; Michal Mandelboim; Yoseph Caraco; Noa Madar-Balakirski; Adva Mechaly; Eilat Shinar; Ran Zichel; Daniel Cohen; Adi Beth-Din; Anat Zvi; Hadar Marcus; Tomer Israely; Nir Paran

doi:10.3390/vaccines10020291

Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera

Yfat Yahalom-Ronen, Noam Erez, Morly Fisher, Hadas Tamir, Boaz Politi, Hagit Achdout, Sharon Melamed, Itai Glinert, Shay Weiss, Inbar Cohen-Gihon, Ofir Israeli, Marina Izak, Michal Mandelboim, Yoseph Caraco, Noa Madar-Balakirski, Adva Mechaly, Eilat Shinar, Ran Zichel, Daniel Cohen, Adi Beth-DinAnat Zvi, Hadar Marcus, Tomer Israely, Nir Paran^*

^*Corresponding author for this work

School of Public Health

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-∆G-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-∆G-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.

Original language	English
Article number	291
Journal	Vaccines
Volume	10
Issue number	2
DOIs	https://doi.org/10.3390/vaccines10020291
State	Published - Feb 2022

Funding

Funders	Funder number
Barzilai Medical Center
Bundeswehr Institute of Microbiology
Clinical Center teams in Israel
Meir Medical Center
Rabin Medical Center
Rambam Health Care Campus
Sheba Medical Center
Hadassah Medical Organization
Tel Aviv University
Ministry of Health, State of Israel

Keywords

BriLife®
COVID-19
Convalescent
Neutralization
SARS-CoV-2
VOC
VSV
Vaccine
Variants

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines10020291

Cite this

Yahalom-Ronen, Y., Erez, N., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., Cohen-Gihon, I., Israeli, O., Izak, M., Mandelboim, M., Caraco, Y., Madar-Balakirski, N., Mechaly, A., Shinar, E., Zichel, R., Cohen, D., ... Paran, N. (2022). Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera. Vaccines, 10(2), Article 291. https://doi.org/10.3390/vaccines10020291

@article{0c4420dcc7384eee942850f2523a92cc,

title = "Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera",

abstract = "The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife{\textregistered} (rVSV-∆G-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-∆G-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants{\textquoteright} mutations. We show that human sera from BriLife{\textregistered} vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife{\textregistered} vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife{\textregistered}-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.",

keywords = "BriLife{\textregistered}, COVID-19, Convalescent, Neutralization, SARS-CoV-2, VOC, VSV, Vaccine, Variants",

author = "Yfat Yahalom-Ronen and Noam Erez and Morly Fisher and Hadas Tamir and Boaz Politi and Hagit Achdout and Sharon Melamed and Itai Glinert and Shay Weiss and Inbar Cohen-Gihon and Ofir Israeli and Marina Izak and Michal Mandelboim and Yoseph Caraco and Noa Madar-Balakirski and Adva Mechaly and Eilat Shinar and Ran Zichel and Daniel Cohen and Adi Beth-Din and Anat Zvi and Hadar Marcus and Tomer Israely and Nir Paran",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

doi = "10.3390/vaccines10020291",

language = "אנגלית",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "2",

}

Yahalom-Ronen, Y, Erez, N, Fisher, M, Tamir, H, Politi, B, Achdout, H, Melamed, S, Glinert, I, Weiss, S, Cohen-Gihon, I, Israeli, O, Izak, M, Mandelboim, M, Caraco, Y, Madar-Balakirski, N, Mechaly, A, Shinar, E, Zichel, R, Cohen, D, Beth-Din, A, Zvi, A, Marcus, H, Israely, T & Paran, N 2022, 'Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera', Vaccines, vol. 10, no. 2, 291. https://doi.org/10.3390/vaccines10020291

TY - JOUR

T1 - Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera

AU - Yahalom-Ronen, Yfat

AU - Erez, Noam

AU - Fisher, Morly

AU - Tamir, Hadas

AU - Politi, Boaz

AU - Achdout, Hagit

AU - Melamed, Sharon

AU - Glinert, Itai

AU - Weiss, Shay

AU - Cohen-Gihon, Inbar

AU - Israeli, Ofir

AU - Izak, Marina

AU - Mandelboim, Michal

AU - Caraco, Yoseph

AU - Madar-Balakirski, Noa

AU - Mechaly, Adva

AU - Shinar, Eilat

AU - Zichel, Ran

AU - Cohen, Daniel

AU - Beth-Din, Adi

AU - Zvi, Anat

AU - Marcus, Hadar

AU - Israely, Tomer

AU - Paran, Nir

PY - 2022/2

Y1 - 2022/2

N2 - The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-∆G-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-∆G-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.

AB - The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-∆G-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-∆G-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.

KW - BriLife®

KW - COVID-19

KW - Convalescent

KW - Neutralization

KW - SARS-CoV-2

KW - VOC

KW - VSV

KW - Vaccine

KW - Variants

UR - http://www.scopus.com/inward/record.url?scp=85124825621&partnerID=8YFLogxK

U2 - 10.3390/vaccines10020291

DO - 10.3390/vaccines10020291

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35214749

AN - SCOPUS:85124825621

SN - 2076-393X

VL - 10

JO - Vaccines

JF - Vaccines

IS - 2

M1 - 291

ER -

Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this